333 related articles for article (PubMed ID: 28754837)
1. p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy.
Bosnakovski D; Gearhart MD; Toso EA; Recht OO; Cucak A; Jain AK; Barton MC; Kyba M
Dis Model Mech; 2017 Oct; 10(10):1211-1216. PubMed ID: 28754837
[TBL] [Abstract][Full Text] [Related]
2. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
4. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.
Wallace LM; Garwick SE; Mei W; Belayew A; Coppee F; Ladner KJ; Guttridge D; Yang J; Harper SQ
Ann Neurol; 2011 Mar; 69(3):540-52. PubMed ID: 21446026
[TBL] [Abstract][Full Text] [Related]
5. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A
J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257
[TBL] [Abstract][Full Text] [Related]
6. Facioscapulohumeral dystrophy myoblasts efficiently repair moderate levels of oxidative DNA damage.
Bou Saada Y; Dib C; Dmitriev P; Hamade A; Carnac G; Laoudj-Chenivesse D; Lipinski M; Vassetzky YS
Histochem Cell Biol; 2016 Apr; 145(4):475-83. PubMed ID: 26860865
[TBL] [Abstract][Full Text] [Related]
7. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
8. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
9. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
10. DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy.
Shadle SC; Zhong JW; Campbell AE; Conerly ML; Jagannathan S; Wong CJ; Morello TD; van der Maarel SM; Tapscott SJ
PLoS Genet; 2017 Mar; 13(3):e1006658. PubMed ID: 28273136
[TBL] [Abstract][Full Text] [Related]
11. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
12. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
13. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
14. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
[TBL] [Abstract][Full Text] [Related]
15. DUX4-Induced Histone Variants H3.X and H3.Y Mark DUX4 Target Genes for Expression.
Resnick R; Wong CJ; Hamm DC; Bennett SR; Skene PJ; Hake SB; Henikoff S; van der Maarel SM; Tapscott SJ
Cell Rep; 2019 Nov; 29(7):1812-1820.e5. PubMed ID: 31722199
[TBL] [Abstract][Full Text] [Related]
16. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones PL
Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108
[TBL] [Abstract][Full Text] [Related]
17. Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy.
DeSimone AM; Leszyk J; Wagner K; Emerson CP
Sci Adv; 2019 Dec; 5(12):eaaw7099. PubMed ID: 31844661
[TBL] [Abstract][Full Text] [Related]
18. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
19. A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death.
Bosnakovski D; da Silva MT; Sunny ST; Ener ET; Toso EA; Yuan C; Cui Z; Walters MA; Jadhav A; Kyba M
Sci Adv; 2019 Sep; 5(9):eaaw7781. PubMed ID: 31535023
[TBL] [Abstract][Full Text] [Related]
20. Dux4 induces cell cycle arrest at G1 phase through upregulation of p21 expression.
Xu H; Wang Z; Jin S; Hao H; Zheng L; Zhou B; Zhang W; Lv H; Yuan Y
Biochem Biophys Res Commun; 2014 Mar; 446(1):235-40. PubMed ID: 24589735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
